Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness

被引:1
|
作者
Andersen, Lars v. B. [1 ,2 ]
Larsen, Martin J. [1 ,2 ]
Davies, Helen [3 ,4 ]
Degasperi, Andrea [3 ,4 ]
Nielsen, Henriette Roed [5 ]
Jensen, Louise A. [1 ,2 ]
Kroeldrup, Lone [1 ]
Gerdes, Anne-Marie [6 ]
Laenkholm, Anne-Vibeke [7 ]
Kruse, Torben A. [1 ,2 ]
Nik-Zainal, Serena [3 ,4 ,5 ]
Thomassen, Mads [1 ,2 ]
机构
[1] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark
[2] Univ Southern Denmark, Clin Genome Ctr, Dept Clin Res, Odense, Denmark
[3] Univ Cambridge, Early Canc Inst, Hutchison Res Ctr, Cambridge Biomed Campus, Cambridge CB2 0XZ, England
[4] Addenbrookes Hosp, Addenbrookes Treatment Ctr Lv 6, Acad Lab Med Genet, Cambridge CB2 0QQ, England
[5] European Sperm Bank, Copenhagen, Denmark
[6] Copenhagen Univ Hosp Rigshospitalet, Dept Clin Genet, Copenhagen, Denmark
[7] Zealand Univ Hosp, Dept Surg Pathol, DK-4000 Roskilde, Denmark
关键词
Breast cancer; Hereditary breast cancer; Non-BRCA1; BRCA2; Whole genome sequencing; Mutational signatures; HRDetect; BRCAness; TUMOR MUTATIONAL BURDEN; BRCA2; MUTATIONS; DEFICIENCY; SIGNATURES; PREDICTOR; LANDSCAPE; GENES; TOOL;
D O I
10.1186/s13058-023-01655-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFamilial breast cancer is in most cases unexplained due to the lack of identifiable pathogenic variants in the BRCA1 and BRCA2 genes. The somatic mutational landscape and in particular the extent of BRCA-like tumour features (BRCAness) in these familial breast cancers where germline BRCA1 or BRCA2 mutations have not been identified is to a large extent unknown.MethodsWe performed whole-genome sequencing on matched tumour and normal samples from high-risk non-BRCA1/BRCA2 breast cancer families to understand the germline and somatic mutational landscape and mutational signatures. We measured BRCAness using HRDetect. As a comparator, we also analysed samples from BRCA1 and BRCA2 germline mutation carriers.ResultsWe noted for non-BRCA1/BRCA2 tumours, only a small proportion displayed high HRDetect scores and were characterized by concomitant promoter hypermethylation or in one case a RAD51D splice variant previously reported as having unknown significance to potentially explain their BRCAness. Another small proportion showed no features of BRCAness but had mutationally active tumours. The remaining tumours lacked features of BRCAness and were mutationally quiescent.ConclusionsA limited fraction of high-risk familial non-BRCA1/BRCA2 breast cancer patients is expected to benefit from treatment strategies against homologue repair deficient cancer cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
    Lars v. B. Andersen
    Martin J. Larsen
    Helen Davies
    Andrea Degasperi
    Henriette Roed Nielsen
    Louise A. Jensen
    Lone Kroeldrup
    Anne-Marie Gerdes
    Anne-Vibeke Lænkholm
    Torben A. Kruse
    Serena Nik-Zainal
    Mads Thomassen
    Breast Cancer Research, 25
  • [2] High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma
    Shahedi, K
    Emanuelsson, M
    Wiklund, F
    Gronberg, H
    CANCER, 2006, 106 (06) : 1237 - 1242
  • [3] Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors
    Fernandez-Ramires, Ricardo
    Gomez, Gonzalo
    Munoz-Repeto, Ivan
    de Cecco, Loris
    Llort, Gemma
    Cazorla, Alicia
    Blanco, Ignacio
    Gariboldi, Manuela
    Pierotti, Marco Alessandro
    Benitez, Javier
    Osorio, Ana
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (11) : 2635 - 2644
  • [4] Molecular classification of familial non-BRCA1/BRCA2 breast cancer
    Hedenfalk, I
    Ringnér, M
    Ben-Dor, A
    Yakhini, Z
    Chen, Y
    Chebil, G
    Ach, R
    Loman, N
    Olsson, H
    Meltzer, P
    Borg, Å
    Trent, J
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) : 2532 - 2537
  • [5] Breast Cancers with Ocular Metastases are Early Onset, Non-Familial and Non-BRCA1/BRCA2 Tumours
    Katarzyna Królewska
    Anna Jakubowska
    Stanisław Zajączek
    Hereditary Cancer in Clinical Practice, 2 (1)
  • [6] Familial non-BRCA1/BRCA2-associated breast cancer
    Eccles, DM
    Pichert, G
    LANCET ONCOLOGY, 2005, 6 (09): : 705 - 711
  • [7] Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers
    Collins, Ian M.
    Milne, Roger L.
    Weideman, Prue C.
    McLachlan, Sue-Anne
    Friedlander, Michael L.
    Cuningham, Kathleen
    Hopper, John L.
    Phillips, Kelly-Anne
    MEDICAL JOURNAL OF AUSTRALIA, 2013, 199 (10) : 680 - 683
  • [8] High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer
    Kristiansen, M
    Knudsen, GPS
    Maguire, P
    Margolin, S
    Pedersen, J
    Lindblom, A
    Orstavik, KH
    JOURNAL OF MEDICAL GENETICS, 2005, 42 (11) : 877 - 880
  • [9] Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
    Pouliot, Marie-Christine
    Kothari, Charu
    Joly-Beauparlant, Charles
    Labrie, Yvan
    Ouellette, Genevieve
    Simard, Jacques
    Droit, Arnaud
    Durocher, Francine
    ONCOTARGET, 2017, 8 (45) : 78691 - 78712
  • [10] Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer
    Felicio, Paula S.
    Grasel, Rebeca S.
    Campacci, Natalia
    de Paula, Andre E.
    Galvao, Henrique C. R.
    Torrezan, Giovana T.
    Sabato, Cristina S.
    Fernandes, Gabriela C.
    Souza, Cristiano P.
    Michelli, Rodrigo D.
    Andrade, Carlos E.
    De Figueiredo Barros, Bruna Duraes
    Matsushita, Marcus M.
    Revil, Timothee
    Ragoussis, Jiannis
    Couch, Fergus J.
    Hart, Steven N.
    Reis, Rui M.
    Melendez, Matias E.
    Tonin, Patricia N.
    Carraro, Dirce M.
    Palmero, Edenir, I
    HUMAN MUTATION, 2021, 42 (03) : 290 - 299